Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3564 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Jerini submits Icatibant to FDA

Jerini has received technical clearance of its electronic common technical document from the agency, which ensures that the documentation meets the agency’s technical standards. Priority review designation, which

Ranbaxy gets FDA approval for valsartan tablets

Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. Valsartan is also indicated for the treatment of heart failure. Jim Meehan,

J&J ADHD drug helps symptom management

The results showed that Concerta achieved a significantly superior reduction in adult ADHD investigator symptom rating scale (AISRS) total score compared to placebo (p=0.012) (mean change was -10.6

Xanafide receives orphan drug designation in Europe

Xanafide (amonafide malate) is an ATP-independent topoisomerase II inhibitor that the company is developing for the treatment of secondary acute myeloid leukemia (AML) and related disorders. Xanafide is

Allozyne raises $30 million and names new CEO

The funding will also accelerate the preclinical development of a second program as well as further exploit the company’s proprietary technology platform. MPM Capital led the financing with

Adventrx chemo drug reduces hypersensitivity reactions

In an established animal model, anaphylactoid clinical reactions were observed following Taxotere administration, including decreased respiration, swelling and tremors. Furthermore, decreases in blood pressure and increases in histamine